Thiamidol in Melasma in Patients of Skin of Color: A Preliminary Report of Efficacy and Safety

Background: Melasma poses significant therapeutic challenges, especially in patients with skin of color, due to the increased risk of post-inflammatory hyperpigmentation. Thiamidol, a novel topical tyrosinase inhibitor, has demonstrated potential efficacy with a favorable safety profile in treating hyperpigmentation disorders. Objective: This case series evaluates the efficacy and safety of Thiamidol in women of skin of color with melasma. Patients and Methods: Ten Indian women with Fitzpatrick skin types III–V and melasma applied 0.2% Thiamidol twice daily for 12 weeks. Outcomes were measured using the modified Melasma Area and Severity Index (mMASI) and patient satisfaction scores. Results: The average reduction in mMASI was 34.4%, with patient satisfaction averaging 62%. Reported adverse effects were minimal and self-limiting. Limitations: A small sample size and the lack of a control group limit generalizability of the results. Future research should explore thiamidol’s efficacy in combination therapies and assess its long-term benefits. Conclusion: Thiamidol is a promising and well-tolerated treatment for melasma in patients with skin of color.